UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 6, 2023
Gyre Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-51173
|
56-2020050
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
12770 High Bluff Drive
Suite 150
San Diego, CA
|
|
92130
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (619) 949-3681
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock
|
|
GYRE
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01. |
Regulation FD Disclosure.
|
On December 6, 2023, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“GNI Japan”), which holds an indirect
controlling interest of Gyre Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing that GNI Japan has amended its consolidated earnings forecast for the full-year 2023 that was previously disclosed on November
6, 2023.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit
furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.
Forward Looking Statements
This report and the press release attached as an exhibit contain forward-looking statements that pertain to future operating performance and that are not
historic facts. Forward-looking statements may include, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility” and similar words that describe future operating activities, business performance, events
or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of GNI Japan and/or the Company, based on information that is currently available to it. As such, these forward-looking statements are
subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking
statements.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits. The following exhibits are being furnished herewith:
|
Exhibit Number
|
|
Exhibit Title or Description
|
| |
|
|
|
|
|
Press Release, dated December 6, 2023
|
| |
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
GYRE THERAPEUTICS, INC.
|
| |
|
|
Date: December 6, 2023
|
By:
|
/s/ Charles C. Wu, Ph.D.
|
| |
Name:
|
Charles C. Wu, Ph.D.
|
| |
Title:
|
Chief Executive Officer
|
Dec 6, 2023
| |
Company Name:
|
GNI Group Ltd.
|
| |
Representative:
|
Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
|
| |
|
(Security Code: 2160, TSE Growth)
|
| |
Contact Person:
|
Chief Financial Officer
Toshiya Kitagawa
|
| |
|
(TEL. 03-6214-3600)
|
GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts
GNI Group Ltd., (TSE Growth security code: 2160, “the Company” or “the Group” or “we” including all the associated companies) today announced that the
Group has updated the consolidated earnings forecast for the full-year 2023, which was published on November 6, 2023, as follows.
| 1) |
Update of Other Income
|
In the transaction with Gyre Therapeutics, Inc. (“Gyre” and formerly named Catalyst Biosciences, Inc. or “CBIO”) previously
disclosed on December 27, 2022, we transferred to CBIO the F351 rights held by the Group outside China. As consideration for the transfer, we received CBIO common and preferred stock. As a result of discussions, only the portion received in common
stock has been recorded in other income.
Subsequently, as disclosed on October 31, 2023, all remaining transactions were successfully completed. On November 22, 2023, GNI
USA irrevocably elected to convert 13,151 shares of Gyre Series X Convertible Preferred Stock, par value $0.001 per share, (“Convertible Preferred Stock”), which was obtained as consideration for the Group’s ex-China F351 rights, into 8,767,333
shares of Gyre common stock. Subject to the Gyre Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, as amended, it is anticipated that 8,767,333 shares of Gyre common stock will be issued to
GNI USA upon such conversion on January 22, 2024. Accordingly, the Group has recognized a total of approximately ¥8,873 million in other income for the shares of common stock after the conversion at US$0.51 per share of common stock (US$7.65 per
share after the 15:1 reverse stock split), which was the closing price of CBIO common stock on the Nasdaq Capital Market on October 30, 2023.
|
1. |
The differences between the previous and the updated 2023 consolidated
earnings forecast for full-year 2023 (January 1, 2023 – December 31, 2023)
|
|
|
|
Revenue
|
|
Operating
profit
|
|
Profit before
tax
|
|
Profit for
the year
|
|
Profit
attributable to
owners of the
parent
|
|
Basic earnings
per share
|
|
|
(JPY Million)
|
|
(JPY Million)
|
|
(JPY Million)
|
|
(JPY Million)
|
|
(JPY Million)
|
|
(JPY)
|
|
|
Previous Forecast (A)
|
|
26,267
|
|
7,280
|
|
6,430
|
|
4,351
|
|
2,005
|
|
42.20
|
|
|
Revised Forecast (B)
|
|
26,300
|
|
15,744
|
|
14,865
|
|
11,234
|
|
8,971
|
|
180.42
|
|
|
Difference (B-A)
|
|
33
|
|
8,464
|
|
8,435
|
|
6,883
|
|
6,966
|
|
-
|
|
|
Difference in ratio (%)
|
|
0.1%
|
|
116.3%
|
|
131.2%
|
|
158.2%
|
|
347.4%
|
|
-
|
|
|
(Reference) 2022 Actual
|
|
17,418
|
|
1,377
|
|
767
|
|
(868)
|
|
388
|
|
8.19
|
|
2. |
Reasons for the differences
|
Due to the above update to Other Income, the Group recognizes ¥8,464 million in operating profit after deducting such expenses as legal fees. As a result of these
factors, the profit items are expected to significantly exceed the full-year forecast announced on November 6, 2023, and we have now revised our full-year consolidated forecast. Please note that this revised forecast does not reflect the latest
Gyre common stock valuation that is marked to market, which is under further discussions.
This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (“the Company”). Any statements contained herein that
pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility”
and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that
is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements.
Consequently, investors are cautioned not to place undue reliance on forward-looking statements.
The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy
or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the
information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.